Martin Shkreli

Investors should watch for near-term downside volatility in SanDisk shares, as the market largely priced in its aggressive earnings beat and strong forward guidance. Long-term investors can view any post-earnings pullback in SanDisk as an opportunity to buy into its massive $93.9 billion data center pipeline and multi-year growth story. Capitalize on SanDisk's aggressive capital return strategy, backed by a newly authorized $14 billion share repurchase program. Traders should monitor Palantir (PLTR) for its historical post-earnings sell-off pattern to find a better entry window during the week following its report. Avoid making any immediate trades on Google (GOOGL), as current discussions lack fundamental catalysts or actionable price targets.

Capitalize on Intel's short-term momentum by buying dips and using disciplined limit orders around the psychological $100 level. Treat AMD as a high-beta trading vehicle for quick swings, keeping in mind that high-profile customer defections to Nvidia can create sudden downward pressure. Buy Taiwan Semiconductor (TSM) as a foundational, picks-and-shovels manufacturing play to safely capture broad semiconductor demand without betting on a single chip designer. Avoid shorting memory stocks like SanDisk heading into earnings events due to extreme binary volatility, and maintain strict caution with high-flying SpaceX shares as they approach the $110 level. Finally, exercise caution with enterprise software investments like Palantir, as emerging artificial intelligence tools threaten to compress traditional software margins.

Consider initiating a long position in Intel (INTC) to capitalize on potential mean reversion relative to the broader semiconductor sector. Avoid trading Micron (MU) zero-day-to-expiration (0 DTE) options due to extreme tail risk and high volatility. Be highly skeptical of short-term price spikes driven by promotional announcements, such as the recent NASDAQ partnership rally in Quantum / D-Wave (QBTS). Watch for tactical trading opportunities around corporate actions like debt exchanges, similar to recent events involving GameStop (GME). Finally, approach high-valuation stocks like Palantir (PLTR) with caution around earnings due to binary event volatility.

Capitalize on Amazon (AMZN) by leveraging its stellar AWS cloud growth for a strong long-term position despite recent trading volatility. Avoid secondary "NeoCloud" providers like Nebius (NEBIUS), as their heavy reliance on reselling third-party compute power presents high structural risks. Target heavily hyped, zero-revenue small-cap biotechs like Queue (Q) for lucrative short opportunities when retail chat room buzz outpaces weak fundamentals. Exercise caution and avoid Replimune (REPLI) despite its positive regulatory momentum, because real-world commercial adoption and doctor utility remain highly questionable. Finally, monitor fundamentally sound companies like AXTI (AXTI) for explosive short-term gains following major quarterly earnings beats.

Take advantage of the recent 9% post-earnings dip in Meta Platforms (META) to accumulate shares, as long-term growth fundamentals remain intact despite heavy artificial intelligence spending.

Prioritize Microsoft (MSFT) as a core tech holding due to its exceptional cloud execution, strong Azure growth, and disciplined capital expenditure strategy that continues to win over the market.

Trade the extreme volatility in Bloom Energy (BE) cautiously by capitalizing on momentum phases while strictly respecting cyclical peaks and potential valuation resets.

Utilize sharp relief rallies in Intel (INTC) for tactical short-term trades, but carefully weigh its cyclical valuation against forward earnings before making long-term commitments.

Look past near-term free cash flow pressures at Amazon (AMZN) and use infrastructure-driven pullbacks to buy, supported by robust 37% year-over-year growth in AWS.

Capitalize on the artificial intelligence boom by investing in NVIDIA ($NVDA**)**, which remains the foundational hardware backbone for the entire sector's expansion.

Consider taking a position in Bloom Energy ($BE**)** to capture surging energy demand driven by new data centers.

Bloom Energy offers a reasonable valuation paired with free cash flow that is projected to double annually over the next few years.

Investors should monitor Bloom Energy closely as rapid revenue growth helps offset its currently low operating margins.

Use this momentum to build exposure to these key artificial intelligence infrastructure players over the near term.

Watch Microsoft Corporation (MSFT) closely around tomorrow's earnings release to evaluate financial performance and growth in its critical cybersecurity segment. The exceptionally strong market sentiment surrounding Broadcom Inc. (AVGO) highlights its notable resilience despite broader market uncertainty. General investors should completely avoid GameStop Corp. (GME), as experts express a distinctly cautious stance and lack any bullish sentiment for the stock.

Immediately avoid or short Capricor Therapeutics (CAPR) due to severe regulatory scrutiny and devastating FDA briefing documents regarding data manipulation. Capitalize on the recent semiconductor sell-off by aggressively buying NVIDIA (NVDA) on market weakness as a long-term growth play targeting its path toward a $10 trillion valuation. Look for value-buying opportunities in Micron Technology (MU) during sharp market pullbacks to capitalize on fundamentally constrained memory supply chains. Exercise extreme caution with speculative quantum computing stocks like D-Wave (QBTS), IonQ (IONQ), and Rigetti (RGTI), considering short positions on overhyped rallies driven by empty press releases. Add Tyra Biosciences (TYRA) to your watchlist ahead of crucial clinical trial data catalysts scheduled for the first and second halves of the year.

Accumulate shares of Intel (INTC) during post-earnings volatility, as the market is offering a strong long-term buying opportunity despite solid fundamentals. Treat recent weakness in mega-cap leaders like Alphabet (GOOGL) as an attractive accumulation phase for patient, long-term investors. Capitalize on high-volume intraday momentum shifts in memory plays like Micron Technology (MU), while preparing for extreme volatility and beta. Avoid volatile consumer health stocks like Hims & Hers Health (HIMS) due to growing market skepticism surrounding peripheral peptide product expansions. Maintain a cautious stance on Broadcom (AVGO) as a potential short candidate due to emerging competitive threats from rivals taking custom silicon market share.

Consider buying the dip on Alphabet (GOOGL) to capitalize on the post-earnings sell-off, as high capital expenditure concerns are likely a temporary overreaction. Target Micron Technology (MU) as a powerful semiconductor momentum play while it approaches the critical $1,000 price milestone. Exercise caution and avoid rushing into Tesla (TSLA) given its sharp 8% to 14% drop, negative free cash flow, and margin compression. Monitor ServiceNow (NOW) for stabilization after volatile post-earnings price action filled its gap in a difficult macro environment for software stocks. Finally, investigate Thermo Fisher Scientific (TMO) for potential short setups if its aggressive 6% to 9% rally proves to be fundamentally unsupported.

Buy the dip on Alphabet Inc. (GOOG / GOOGL) as surging cloud revenues and massive AI infrastructure demand outweigh near-term negative free cash flow. Target a near-term price of $1,000 to $1,100 for Micron Technology (MU) as booming AI data center memory demand drives the stock higher from current levels. Utilize Super Micro Computer (SMCI) trading around $31 to $32 as a high-beta proxy to capture short-term momentum from hyperscale AI server deployments. Accumulate Arrowhead Pharmaceuticals (ARWR) in the $88 to $93 range as a strong long opportunity following recent positive clinical trial data. Treat Cerebras Systems (CBRS) as a strictly tactical trading vehicle given its extreme intraday volatility and poor profit margins near the $200–$220 range.

Buy Adobe (ADBE) on pullbacks after its Morgan Stanley downgrade dip, as the sell-off is seen as overdone.
Short Danaher (DHR) following its 14% post-earnings drop, as weak growth and a messy acquisition story suggest further downside.
Accumulate Apple (AAPL) on dips, with recent large purchases around $227 indicating high conviction.
Consider Biohaven (BHVN) for a pre-catalyst trade ahead of upcoming clinical readouts, but size for binary risk.
Active traders can scalp Micron (MU) swings around the $932 level, though rallies may quickly fade.

Investors should maintain long positions in Micron (MU) and NVIDIA (NVDA), as rising memory prices and high demand from price-insensitive cloud providers continue to drive the semiconductor sector. Clinical data catalysts are approaching for 10x Genomics (TXG) and Scion (SION), though these remain high-risk "binary" events that will cause significant price swings this summer. For those seeking a contrarian software play, Adobe (ADBE) is reaching an attractive entry point after recent weakness, while Microsoft (MSFT) remains the preferred core holding for stable tech exposure. Active traders should look to short Bloom Energy (BE) due to its high valuation and persistent price "bleeding," or Hut 8 (HUT) following its recent news-driven spike. Monitor AMD closely for official confirmation on GPU shipping dates to verify if rumored production delays are impacting the stock's timeline.

Investors should consider Micron Technology (MU) as a high-conviction "buy the dip" opportunity, with potential earnings reaching $34-$43 per share by 2027 as it challenges NVIDIA (NVDA) for net income dominance. While the broader semiconductor sector has faced technical liquidations, Hynix remains a recommended safe haven for those seeking direct exposure to High Bandwidth Memory. Avoid Intuitive Surgical (ISRG) and Abbott Laboratories (ABT) at current levels, as their valuations remain unattractive despite recent price drops. In the biotech space, exercise extreme caution with 10x Genomics (TXG) ahead of its August Phase 3 data, as the options market is currently pricing in a high probability of failure. For long-term growth, prioritize major tech leaders like Apple, Amazon, and Alphabet following recent market volatility, as fundamental value is expected to prevail over temporary price dips.

Despite the current semiconductor sell-off, Micron (MU) and SK Hynix remain high-conviction long-term plays in the memory sector, though investors should wait for Google and Meta earnings to confirm continued AI infrastructure spending. Ultragenix (RARE) is highlighted as a top-tier long opportunity with the potential to double in value if its Sanfilippo drug is approved and Phase 3 Angelman Syndrome data succeeds later this year. PayPal (PYPL) is positioned as a strategic acquisition target, with expectations that the company will be sold to a larger bidder like SpaceX within the next 12 months. For speculative biotech traders, Tenax Therapeutics (TENX) offers a high-risk binary event ahead of its Levosimendan trial data expected by late August. Conversely, investors should consider shorting Oklo (OKLO) and Lucid (LCID), while avoiding Apple (AAPL) at its current valuation.

Avoid buying the dip in IBM following its negative earnings pre-announcement, as it signals a broader contraction in corporate IT spending that could weigh on the entire tech sector. Consider a short position on Bristol Myers Squibb (BMY) due to a failing product pipeline and looming revenue cliffs for its core franchises. Take a bearish stance on Micron (MU) and the memory sector, as the IBM news suggests cyclical risks for hardware spending are being underestimated. For a high-conviction long opportunity, look to Alnylam (ALNY), which is currently viewed as significantly undervalued. Conversely, look for a contrarian entry point in Adobe (ADBE) on its recent weakness, as its fundamental business model remains stronger than enterprise peers like IBM.

Consider Q32 Bio (Q32) as a high-conviction long-term play following positive Phase II results for Benpigabart, a biologic for Alopecia Areata that lacks the "Black Box" safety warnings of current JAK inhibitors. With a registration-directed Phase III program slated for early 2027, the drug aims to capture a $5 billion market by offering a safer, more durable alternative to Olumiant and Litfulo. Conversely, maintain a bearish outlook on Agenus (AGEN), viewing recent price spikes as a "dead cat bounce" and targeting a return to the $3.00–$3.50 range. In the semiconductor space, exercise caution with Micron (MU) and Western Digital (WDC), as high capital expenditures and crowded positioning may limit near-term upside despite AI demand. Finally, remain skeptical of Bitcoin (BTC) and the broader memory trade, focusing instead on free cash flow over earnings per share to navigate current market volatility.